T he manifestations of small vessel vasculitides are often protean and may involve both the skin and internal organs, including the kidney. To avoid potentially life-threatening complications, correct differential diagnosis and exclusion of internal organ involvement are particularly important. Previously, cryoglobulinaemic vasculitides were assumed to be primary or essential. It has now become evident that the majority of cryoglobulinaemic vasculitides are secondary manifestations of other diseases, especially of viral origin, such as chronic hepatitis C virus (HCV). This recognition offers an opportunity for causal rather than symptomatic therapy of these vasculitides. The different causes, types and complications of cryoglobulinaemic vasculitis, including glomerulonephritis, are reviewed here.
DEFINITIONS AND CLASSIFICATIONS
Cryoglobulins are cold-precipitable immunoglobulins from serum. Cryoglobulinaemia remains asymptomatic in most cases but can lead to immune complex tissue deposition, causing cryoglobulinaemic vasculitis. Based on the classification introduced in 1974, 1 three main and one additional 2 categories of cryoglobulins are currently recognised (table 1) .
Cryoglobulinaemic vasculitis belongs to the large group of cutaneous vasculitides that originate from inflammation in the small or medium sized vasculature (the so-called small vessel vasculitides), leading to clinically apparent skin lesions, and in some cases also to internal organ involvement. 6 Vasculitis can be classified using clinical (tissues and vasculature presumed to be involved on clinical grounds), histopathological (tissues and vessels involved, type of vascular destruction) or immunopathological (identified molecular pathogenesis) terms, or their combination. [6] [7] [8] The most widely used classification today is that coined by the Chapel Hill consensus conference which is mainly based on anatomical distinctions of the dominant vessels affected (table 2) . 8 For the clinician, establishing the hypothesis that a patient may have small vessel cutaneous vasculitis is the first step. From a pathogenetic point of view, the largest group of small vessel dermal vasculitides consists of the immune complex mediated types. [6] [7] [8] These include mainly cryoglobulinaemic vasculitis, Henoch-Schönlein purpura, urticaria vasculitis and vasculitis associated with malignancy (see table 2 for details).
Vasculitis affecting not only the small but also medium sized vessels includes the so-called pauciimmune forms (table 3) . 8 Other disorders causing cutaneous vasculitis include the following: inflammatory bowel disease, Behçet's disease and septic emboli, as in bacterial endocarditis, and EED (erythema elevatum diutinum), an immune complex vasculitis of unknown aetiology. 6 It may be associated with HIV infection and usually presents with symmetrically distributed purple plaques and nodules on the extensor surfaces. 13 
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PATHOGENESIS/AETIOLOGY
Type II and III (mixed) cryoglobulinaemia is strongly associated with HCV infection, and since the first reports 15 the causative role of HCV is now widely acknowledged. 4 16 The presence of cryoglobulins increases with duration of HCV infection; 30-50% of HCV positive patients have mixed cryoglobulins while in selected patients with chronic HCV infection, cryoglobulins are found in 55-90% of cases. [17] [18] [19] Rheumatoid factor is positive in most patients with chronic HCV infection. 18 Type II cryoglobulinaemia is more strongly associated with HCV than type III cryoglobulinaemia (that is, 90% and 70%, respectively). 12 An association of cryoglobulinaemia with chronic hepatitis B virus (HBV) infection has been suggested but is highly questionable as the prevalence of cryoglobulins in HBV infected patients is similar to that in other chronic liver diseases. 17 At best, approximately 2% of mixed cryoglobulinaemic vasculitides seem to be attributable to HBV infection, according to one study. 20 Type III cryoglobulins have been reported to occur as a transient phenomenon in many different infections. 4 It is thought that partially uncontrolled B cell clone proliferation, which can often be detected in patients with long standing HCV infection, underlies the formation of mixed The aetiologies of cryoglobulinaemia were found to be 75% infectious, 24% autoimmune and 6% neoplastic in one study. 23 cryoglobulins. 16 21 Indeed, HCV is also a lymphotropic virus and it is worth noting that 6-28% of patients with type II cryoglobulinaemia develop symptomatic lymphoma after 4-10 years of follow-up. 6 21 Importantly, non-viral liver disease (for example, due to alcohol abuse or immunological autoimmune hepatitis) has also been associated with increased rates of mixed cryoglobulin formation. 17 Other associations of mixed cryoglobulins are summarised in table 4.
MANIFESTATIONS OF CRYOGLOBULINAEMIC VASCULITIS AND CLINICAL APPROACH
Between 2% and 15% of cryoglobulin positive patients are considered to develop cryoglobulinaemic vasculitis. 6 24 Frequent symptoms and serological findings are listed in table 5. An important first diagnostic step is detection of serum cryoglobulins. For correct detection, blood samples must be constantly kept at 37˚C on the way to the laboratory. Cold precipitation can be Ca ++ dependent and may take up to a week, as described previously. 2 25 Encountered cryoglobulin levels range from as low as 0.05 g/l to 10 g/l and sometimes higher, depending on the type of cryoglobulin and the laboratory. 1 2 26 Standard detection uses immunoelectrophoresis and immunofixation; the more sensitive methods for detection of oligoclonal components of type III cryoglobulins are immunoblotting and two dimensional electrophoresis. 4 Cryoprecipitates may deplete HCV antibody and HCV antigens from serum, leading to a false negative hepatitis serology. This can be overcome by paired testing from both the serum and cryoprecipitate. 4 
DERMATOLOGICAL SYMPTOMS AND SIGNS
The clinical hallmark of cutaneous vasculitis is palpable purpura that usually occurs in the lower extremities. Possible manifestations of purpura are: (i) multiple small papules covering larger skin areas (fig 1A, from a patient with cutaneous small vessel vasculitis); (ii) larger confluent necrotising lesions (fig 1B, from a patient with polyarteriitis nodosa); and (iii) livedo racemosa, marble-like changes to the skin that are mostly present in necrotising vasculitides ( fig 1B) . These patterns may occur singularly, serially or in conjunction, and they are not specific to the type of vasculitis, thus precluding a diagnosis on clinical grounds alone. Furthermore, vasculitis of the skin must be differentiated from an array of non-vasculitic lesions mimicking its aspect that include plain urticaria, which denotes a non-vasculitic itchy oedema of multiple or idiopathic origin (fig 1C) , prurigo simplex, showing itchy papular lesions of a generally benign nature that may be associated with liver disease, diabetes and paraneoplasia ( fig 1D) , 27 or from erythema multiforme (not shown). (fig 2A, C) which developed into late necrosis after several weeks of corticosteroid treatment ( fig 2D) . In addition, small macular necrotic lesions can be seen ( fig 2B) . Necrosis of the toes has also been described with cryoglobulinaemic vasculitis (not shown).
To secure the diagnosis, a skin biopsy is always required to define the histopathology, to search for deposition of immune complexes and complement, and for the exclusion of nonvasculitic cutaneous conditions such as pigmented purpuric eruptions, scurvy, atheroembolic or thrombotic disease that may clinically mimic vasculitis. 6 28 Figure 2E and 2F show the histopathological pattern of leucocytoclastic vasculitis in the patient with cryoglobulinaemic vasculitis. Leucocytoclasis denotes the presence of leucocytic vascular/perivascular infiltrates and leucocytic cell dust. 6 28 However, such a pattern in haematoxylin-eosin stained specimens is seen in almost all vasculitides, independent of aetiology. 6 28 Only additional analysis for subtypes of deposited immune complexes and possible complement allow for further aetiological differentiation.
A complete vasculitis workup should also include fundoscopy 29 and a comprehensive panel of immune serologies. Investigations searching for infections and neoplasms may also be necessary to establish the type and aetiology of the vasculitis, as well as the degree of extradermal organ involvement. 6 
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RENAL COMPLICATIONS
All three main types of cryoglobulinaemic vasculitis can lead to kidney disease, as summarized in table 6. In brief, membranoproliferative glomerulonephritis (MPGN) type I is typical. Up to 10-30% of patients with chronic HCV infection develop MPGN I. Very recently, 146 patients with cryoglobulinaemic vasculitisassociated renal disease from Italy were studied. The mean-age was 52 years, 87% of patients were found to be infected with HCV (98% genotypes 1b and 2), ,85% had MPGN I and ,7% had mesangioproliferative glomerulonephritis on renal biopsy. 53 Generally, cryoglobulin associated MPGN I can present with either proteinuria (41%), the nephritic syndrome (21%), the nephritic syndrome (14%; marked by urinary erythrocyte acanthosis, fig 3) , and both chronic (12%) and acute (9%) renal failure. 12 33 36 53 Extrarenal symptoms such as skin involvement may be absent in 30-80% of cases. 37 53 On histology MPGN I exhibits subendothelial deposition of cryoglobulin immune complexes and often complement c3 in the glomerular basement membrane. Because of subsequent mesangial cell proliferation, there is marked thickening of the glomerular basement membrane and glomerular hypercellularity (fig 4) .
TREATMENT OF CRYOGLOBULINAEMIC VASCULITIS
Asymptomatic cryoglobulinaemia merits no treatment. Therapy of secondary cryoglobulinaemic vasculitis is aimed at the primary disease, as summarised in table 7. For HCV associated cryoglobulinaemic vasculitis type II, antiviral strategies aiming at cure of HCV infection, as outlined in table 7, have been shown to be clearly superior to conventional immunosuppression. 46 However, some controversy remains concerning the effectiveness of anti-HCV treatment in patients with active cryoglobulinaemic vasculitis. 47 Recently, an entirely new approach of treating cryoglobulinaemic vasculitis by direct blockage of complement C5 has been suggested and has been demonstrated to be effective in a mouse model. 48 This finding is of potential interest for future treatment strategies in humans.
PROGNOSIS
The prognosis of mixed cryoglobulinaemic vasculitis is benign in 50% of cases. However, one third of cases are reported to have a moderate to severe course, particularly because of renal and/or hepatic insufficiency. Consequently, 10 year survival rates are significantly lower than in the normal population. 20 According to recent data from small patient numbers, antiviral treatment may cure or control HCV associated mixed cryoglobulinaemic vasculitis and possibly improve prognosis. 38 In previous studies, the survival of MPGN I patients not stratified for aetiology was significantly lower than in the normal population: 50% of patients progressed to end stage renal disease (ESRD) within 10 years and the recurrence rate in patients with renal transplants was 30-70%. A number of recent small studies have reported successful MPGN I treatment using antiviral strategies (see table 7 ). Further large studies and follow-up data are needed to determine the benefit of HCV treatment on the course of both cryoglobulinaemic vasculitis and MPGN I. The topic is of importance as MPGN I is a major cause of glomerulonephritis all over the world. 49 The prognosis of cryoglobulinaemia with no identified underlying disease (essential mixed cryoglobulinaemia) is not well known, and renal involvement is associated with a poor prognosis (renal failure in 10% of patients). 50 However, recently a potentially promising therapeutic approach using the CD-20 antibody rituximab has been suggested. 
CONCLUSIONS AND PERSPECTIVE
In recent years, considerable progress has been made in the availability of routine diagnosis and epidemiological study of hepatitis C infection, clearly demonstrating its association with cryoglobulinaemia of types II and III. The concept that chronic HCV infection underlies the majority of cases of cryoglobulinaemia is now widely acknowledged. On average, HCV infected patients develop cryoglobulinaemia in 30-50% of cases and MPGN type I in 10-30% of cases. Up to 2-15% of patients with cryoglobulinaemia develop overt cryoglobulinaemic vasculitis. Treatment should be directed towards aetiology rather than symptomatic. HCV infection, as the most common possible underlying condition, has to be excluded in every case. Experience with and data on antiviral treatment options have grown considerably in recent years. A 48 week course of combined peginterferon and ribavirin represents the current gold standard of anti-HCV therapy. HCV, hepatitis C virus; IFN, interferon; MPGN, membranoproliferative glomerulonephritis. Rituximab is contraindicated or must be used with caution in patients with renal failure. Antiviral treatment is not routinely recommended for patients with the following: hepatic decompensation, severe uncontrolled psychiatric disorder or severe cytopenia. Rituximab is contraindicated or must be used cautiously in patients with renal failure. Positive predictors for response to antiviral therapy include: genotypes 2 or 3, low HCV RNA levels, age (40 years, absence of liver cirrhosis/bridging fibrosis/steatosis, lighter body weight and non-black ethnicity. 38 39 In renal involvement with proteinuria, symptomatic treatment with angiotensin-converting enzyme inhibitors, angiotensinreceptor blockers and diuretics is generally advised. 
